UK Outlook 2018: IVDs Faces Up To Digital, Pathology Consolidation And IVDR Challenges
Executive Summary
UK diagnostics manufacturers face major challenges in adapting to the EU IVDR and to the possible changes that Brexit will bring in regulation, trading conditions, costs and access to talent. In addition, the industry will have to factor in a restructuring of pathology networks and future NHS procurement changes, all while transitioning to digital health-care concepts, says IVD industry association chief Doris-Ann Williams.
You may also be interested in...
Digital And Connected Care Are Pushing On An Open Door – But Is Medtech Ready?
Digital health care will one day simply be "health care" in the same way that genomic medicine will simply become "medicine." But between then and now, there is much distance to cover – a lot of it in the minds of stakeholders who, maybe reluctantly, see it as a risky strategy. But the emerging consensus is that it represents opportunity.
One UK Notified Body To Be Phased Out This Year As It Moves To Sweden
Notified bodies are busy repositioning themselves this year in the light of Brexit. One UK notified body is relocating to Sweden, but it is playing down Brexit and emphasizing the benefits of centralization.
UK Outlook 2018: Medtech Readies For Change To FOM System Of Value-Based Procurement
For UK medtech companies, a new NHS value-based procurement system is coming in the shape of the Future Operating Model. ABHI COO Nishan Sunthares explains what the FOM will mean for UK medtechs when it applies fully later this year.